Synairgen investor relations. Dec 31, 2022 · The Synairgen team is ever grateful for the support of its loyal investors, partners and staff in a crucial year where it has researched the rationale for, and is gearing up to execute on, the most appropriate strategy for the development of SNG001. Jan 16, 2025 · Find out how to deal online from £1. At the General Meeting Oct 4, 2022 · Richard Marsden, CEO of Synairgen, commented: "The data from the ACTIV-2 trial in the US showing a non-significant but encouraging 86% relative risk reduction in hospitalisation following treatment with SNG001 in home-based patients are very interesting when considered in the context of therapeutic options for the management of non-hospitalised Shareholders with interests of over 3% (Significant Shareholders), as advised to the Company, are listed above. Investor Conference - SynairgenInvestor Conference Careers By joining us you will become part of a collaborative and supportive team driven to make a difference for people with severe viral lung infections. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. First Name Last Name Email Analyse the historical data and Synairgen share price performance charts on this page. 50 in a SIPP, ISA or Dealing account. com Tel: +44 (0) 20 3709 5701 Notes for Editors About Mar 28, 2025 · Synairgen plc ('Synairgen' or the 'Company') Result of General Meeting, Cancellation and Re-registration Southampton, UK - 28 March 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, both resolutions as The Company’s year-end is 31 December. The committee also reviews, and reports on, reports from the Tel: + 44 (0) 20 7260 1000 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Namrata Taak, Lucy Featherstone cscsynairgen@consilium-comms. Oct 10, 2024 · Level the playing field with access to the latest investment research. Investor Relations – Filings and financial statements from SYNAIRGEN PLC. Click on a thumbnail to download the PDF version of the factsheet. Phillip Monk is stepping down from the Board and will London Stock Exchange | London Stock Exchange null Jun 30, 2023 · RNS Number : 7084F Synairgen plc 26 September 2024 Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024 Southampton, UK – 26 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta Mar 3, 2022 · Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. These documents Jun 7, 2023 · The Company’s year-end is 31 December. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of COVID-19 as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. Factsheets Explore our factsheets below. com Tel: +1 516-606-6545 Notes for Editors About Synairgen Southampton, UK – 17 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, will announce its preliminary statement of audited results for the year ended 31 December 2022 on Thursday 27 April 2023. Synairgen PLC (LSE:SNG) investor relations materials: earnings calls, slides & pdfs, and letter to shareholders. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen appoints Dr Marcin Mankowski as Chief Medical Officer New full-time role created as Synairgen progresses clinical development strategy Southampton, UK – 3 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum Jan 15, 2025 · Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Southampton, UK - 15 Sep 20, 2022 · RNS Number : 9327Z Synairgen plc 20 September 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen to present 60 and 90-day Long COVID data from Phase 3 SPRINTER study in hospitalised COVID-19 patients at IDWeek 2022 · Analysis of 60 and 90-day data from Phase 3 SPRINTER trial in hospitalised COVID-19 patients showed that SNG001 reduced risk of recognised Long COVID symptoms · Company Sep 5, 2022 · Released : 05 Sep 2022 07:00 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces its collaboration on the UNIVERSAL trial, an observational study of patients hospitalised due to a range of respiratory viruses · Led by the Clinical Trials Unit at the University of Southampton, supported by Synairgen and funded by Janssen · Will explore the varied nature of acute respiratory viral Dec 31, 2022 · Southampton, UK – 27 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its preliminary statement of audited results for the year ended 31 December 2022. Synairgen plc (‘Synairgen’ or the ‘Company’) Board Change Southampton, UK – 5 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that, following 18 years of service, Dr. Apr 8, 2025 · Synairgen plc (‘Synairgen’ or the ‘Company’) Result of General Meeting, Cancellation and Re-registration Southampton, UK – 28 March 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, both Apr 9, 2025 · Description of the Business Directors, Committees and their roles Audit Committee The committee has primary responsibility for ensuring that the financial performance of the Group is properly measured and reported on, reviewing the interim financial information and annual financial statements before they are submitted to the Board. Presentations Presentations Financials 2024 2023 2022 2021 ATS 2024 Poster Presentation21st May 2024 Oct 10, 2014 · Synairgen PLC (AIM:SNG, OTC:SYGGF) chief executive Richard Marsden talks to Proactive following the release of full year results for calendar year 2022 - a year he says was "quite challenging at times. Presentations Presentations Financials 2024 2023 2022 2021 ATS 2024 Poster Presentation21st May 2024 About Synairgen Synairgen plc discovers and develops drugs for respiratory diseases. to develop a LOXL2 inhibitor. Check out the latest publications, news and insider trades. Highlights (including post period-end) Operational Completed further analysis of Jan 15, 2025 · Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Southampton, UK - 15 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces Jun 30, 2022 · Released : 29 Sep 2022 07:00 RNS Number : 0807B Synairgen plc 29 September 2022 Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2022 Southampton, UK - 29 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta Access our content library for valuable insights and inspiration from leading capital markets experts. We report our financial results on a half yearly basis. Presentations Presentations Financials 2024 2023 2022 2021 ATS 2024 Poster Presentation21st May 2024 The Company’s year-end is 31 December. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. Oct 20, 2021 · Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK Sep 7, 2022 · Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces positive data from additional assessments of lung sputum samples from its Phase 2 clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory Oct 30, 2024 · Synairgen plc ('Synairgen' or the 'Company') Exercise of Share Options and Total Voting Rights Southampton, UK - 30 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that it has allotted a total of 1,285,722 new ordinary shares of 1 penny Sep 21, 2021 · Disclaimer Synairgen plc published this content on 21 September 2021 and is solely responsible for the information contained therein. London Stock Exchange | London Stock Exchange null Jun 30, 2023 · RNS Number : 7084F Synairgen plc 26 September 2024 Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024 Southampton, UK – 26 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta Mar 3, 2022 · Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 Publication of Annual Report and Accounts for the year ended 31 December 2024 29th September 2025 Business Update - 4th September 2025 4th September 2025 Board and Executive Leadership Changes 16th May 2025 Shares Admitted to Trading on Asset Match 8th May 2025 John Bradshaw appointed Investors Reports & Presentations The Company’s year-end is 31 December. Southampton, UK - 6 July 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 5 July 2022 the Board of Synairgen granted options ('Options') over 6,407,130 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an Sep 7, 2022 · Released : 07 Sep 2022 07:00 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients Southampton, UK - 7 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum Dec 31, 2022 · The Synairgen team is ever grateful for the support of its loyal investors, partners and staff in a crucial year where it has researched the rationale for, and is gearing up to execute on, the most appropriate strategy for the development of SNG001. Explore thought leadership articles, annual Investor Relations reports, and more. Jun 30, 2021 · Investors Reports & Presentations The Company’s year-end is 31 December. Shares provides unbiased commentary, ideas, views and news on stocks, funds, pensions and savings. Presentations Presentations Financials 2024 2023 2022 2021 ATS 2024 Poster Presentation21st May 2024 Subscribe to news 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 Publication of Annual Report and Accounts for the year ended 31 December 202429th September 2025 Business Update - 4th September 20254th September 2025 Board and Executive Leadership Changes16th May 2025 Shares Admitted to Trading on Asset Match8th May 2025 John Access our content library for valuable insights and inspiration from leading capital markets experts. View SYGGF financial statements in full. Synairgen plc (‘Synairgen’ or the ‘Company’) Result of General Meeting and Total Voting Rights Southampton, UK – 16 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, all resolutions Mar 28, 2025 · Synairgen plc (‘Synairgen’ or the ‘Company’) Proposed cancellation of admission of Ordinary Shares to trading on AIM Re-registration as a private limited company Adoption of New Articles of Association and Notice of General Meeting Southampton, UK – 11 March 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation May 25, 2021 · ('Synairgen' or the 'Company') Posting of Annual Report and Accounts and Notice of Annual General Meeting Southampton, UK - 25 May 2021: Synairgen plc (LSE: SNG), the respiratory company developing inhaled interferon beta (IFN-beta) for the treatment of severe viral lung infections, announces that the Annual Report and Accounts for the year ended 31 December 2020 and Notice of Annual General Synairgen plc (‘Synairgen’ or the ‘Company’) Update on trading post cancellation Southampton, UK – 3 April 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, provides an update post its recent General Meeting held on 28 March 2025. Jun 30, 2022 · Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2023 Southampton, UK – 21 September 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces its unaudited interim results for the Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. com. Synairgen PLC balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. Apr 2, 2025 · Synairgen plc ('Synairgen' or the 'Company') Update on trading post cancellation Southampton, UK - 3 April 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, provides an update post its recent General Meeting held on 28 March 2025. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen appoints Dr Marcin Mankowski as Chief Medical Officer New full-time role created as Synairgen progresses clinical development strategy Southampton, UK – 3 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum Jan 15, 2025 · Synairgen plc ('Synairgen' or the 'Company') £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Southampton, UK - 15 Sep 20, 2022 · RNS Number : 9327Z Synairgen plc 20 September 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen to present 60 and 90-day Long COVID data from Phase 3 SPRINTER study in hospitalised COVID-19 patients at IDWeek 2022 · Analysis of 60 and 90-day data from Phase 3 SPRINTER trial in hospitalised COVID-19 patients showed that SNG001 reduced risk of recognised Long COVID symptoms · Company Sep 15, 2022 · Southampton, UK - 15 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, will announce its unaudited half-year results for the 6 months ended 30 June 2022 on Thursday 29 September 2022. Southampton, UK - 6 July 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 5 July 2022 the Board of Synairgen granted options ('Options') over 6,407,130 ordinary shares of one pence each in the capital of the Company ('Ordinary Shares') at an Sep 7, 2022 · Released : 07 Sep 2022 07:00 Synairgen plc ('Synairgen' or the 'Company') Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients Southampton, UK - 7 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum Synairgen is a drug discovery and development company founded to combat severe respiratory diseases. Our people are committed to our purpose of restoring lives with pandemic-ready respiratory treatments we can all believe in. . Dec 19, 2024 · For the avoidance of doubt, the EU Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Placing Shares. Information on stock, financials, earnings, subsidiaries, investors, and executives for Synairgen. We were founded in 2003 as a spin-out from the University of Southampton. Use the PitchBook Platform to explore the full profile. In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 13. Synairgen plc (‘Synairgen’ or the ‘Company’) Martin Murphy appointed as Non-Executive Director Southampton, UK – 16 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the appointment of Martin Murphy to the Board as an Synairgen plc (‘Synairgen’ or the ‘Company’) £18 million raised to fund Phase 2 INVENT clinical trial of SNG001 in ventilated patients with severe viral lung infections Southampton, UK – 15 January 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta Jun 27, 2024 · The Synairgen team is ever grateful for the support of its loyal investors, partners and staff in a crucial year where it has researched the rationale for, and is gearing up to execute on, the RNS Number : 4597T Synairgen plc 15 November 2023 Synairgen plc ('Synairgen' or the 'Company') Grant of Options Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 14 November 2023 the Board of Synairgen granted Search companies, ETFs and Managed Funds for latest share prices, M&A, institutional ownership, analyst reports and stock quotes - FT. Mar 11, 2025 · Synairgen plc ('Synairgen' or the 'Company') Proposed cancellation of admission of Ordinary Shares to trading on AIM Re-registration as a private limited company Adoption of New Articles of Association and Notice of General Meeting Southampton, UK - 11 March 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the May 23, 2023 · Southampton, UK - 23 May 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that the Annual Report and Accounts for the year ended 31 December 2022 and Notice of its 2023 Annual General Meeting (AGM) have been posted to shareholders. Mar 28, 2025 · Synairgen plc ('Synairgen' or the 'Company') Result of General Meeting, Cancellation and Re-registration Southampton, UK - 28 March 2025: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that, at the General Meeting held earlier today, both resolutions as Sep 15, 2022 · Southampton, UK - 15 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, will announce its unaudited half-year results for the 6 months ended 30 June 2022 on Thursday 29 September 2022. Apr 5, 2022 · RNS Number : 2313H Synairgen plc 05 April 2022 Synairgen plc ('Synairgen' or the 'Company') Synairgen to present further analysis of Phase 3 SPRINTER trial in hospitalised patients with COVID-19 at the ATS 2022 International Conference Southampton, UK - 5 April 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing Sep 30, 2021 · Synairgen plc (‘Synairgen’ or the ‘Company’) Non-Executive Director Appointment Southampton, UK – 30 September 2021: Synairgen plc (LSE: SNG), the drug discovery, development and News TR-1/Options Press Release Archive 2025 2024 2023 2022 2021 2020 2019 2018 Holding (s) in Company 17th January 2025 Subscribe to news Get Synairgen's latest news sent to your inbox by providing your email address below. View Synairgen (SYNG) share chat commentary here. Copies of the Report and accounts can be found here. Free registration. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom. Join other Synairgen investors to discuss value movements, price rumours & more. Sep 30, 2025 · Synairgen is a UK-based respiratory company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections . Sep 6, 2017 · finnCap Geoff Nash, James Thompson (Corporate Finance) Stephen Norcross, Simon Johnson (Corporate Broking) Tel: + 44 (0) 20 7220 0500 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott / Philippa Gardner / Laura Thornton synairgen@consilium-comms. Oct 20, 2025 · Should You Buy or Sell Synairgen Stock? Get The Latest SNG Stock Analysis, Price Target, Dividend Info, and Headlines at MarketBeat. We do not use your email address for any other purpose. Distributed by Public, unedited and unaltered, on 21 September 2021 07:11:03 UTC. " Marsden discusses the UK-based respiratory company's clinical development plan to take the Analyse the historical data and Synairgen share price performance charts on this page. Jan 13, 2021 · Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces commencement of dosing in its international Phase III study of inhaled Oct 10, 2014 · Published: 03:00 10 Oct 2014 EDT Synairgen (AIM:SNR) - Investor Presentation October 9th 2014 May 24, 2021 · Press release Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces results of in vitro studies showing antiviral activity of interferon May 16, 2022 · Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the first presentation of the full data analysis from its Phase 3 SPRINTER trial evaluating the efficacy and safety of SNG001 in patients hospitalised with COVID-19. Sep 25, 2024 · Synairgen plc ('Synairgen' or the 'Company') Interim results for the six months ended 30 June 2024 Southampton, UK - 26 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces its unaudited interim results for the six Oct 12, 2016 · Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Discover SNG001, our breakthrough treatment for COVID-19. 0%, which comprises the holding of TFG Asset Management UK LLP and the directors’ beneficial holdings. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly Feb 15, 2021 · Southampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of New Chairman Posting of Report and Accounts and Notice of AGM Southampton, UK – 18 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that Simon Shaw will retire as Apr 3, 2025 · In the meantime, investors can still trade shares via Asset Match, a private trading platform, which Synairgen has committed to using until at least April 2027. The company has a licensing and collaboration agreement with Pharmaxis Ltd. Great investment tools with live data. Jun 30, 2022 · Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. Equity research, broker reports, and media content available to private and non-institutional investors. Our technical summary section provides analysis on Synairgen share price buy/sell indicators using real-time data (or discuss the Synairgen (SYNG) stock price today with other investors in the Synairgen LON share price and sentiment chat forum). com Tel: +44 (0) 20 3709 5700 MKC STRATEGIES, LLC (US Media Relations) Mary Conway MConway@MKCStrategies. Synairgen PLC (OTC:SYGGF) investor relations materials: earnings calls, slides & pdfs, and letter to shareholders. Dec 31, 2021 · Tel: + 44 (0) 20 7260 1000 Consilium Strategic Communications (Financial Media and Investor Relations) Mary-Jane Elliott, Jessica Hodgson, Namrata Taak cscsynairgen@consilium-comms. At the General Synairgen plc discovers and develops drugs for respiratory diseases. com Tel: +1 516-606-6545 Notes for Editors About Synairgen Dec 23, 2022 · Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces the online publication Jun 29, 2023 · Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. It develops SNG001, inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-Ã ), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-Ã that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. v50kj sabww 21g9q6 eh fedgn t9w yjrfph inxl kzqvr5 hxu5u